Previous Article | Next Article 
Journal of Clinical Microbiology, September 1999, p. 2910-2912, Vol. 37, No. 9
Departments of
Virology1 and Infectious
Diseases,2 Pitié-Salpêtrière
Hospital, Paris, France
Received 4 January 1999/Returned for modification 19 April
1999/Accepted 14 June 1999
In order to analyze the impact of protease gene polymorphism on
response to regimens containing a protease inhibitor, the entire
protease coding domain from 58 human immunodeficiency virus type 1 (HIV-1)-infected patients who were protease inhibitor naive was
sequenced before therapy was started. Plasma HIV-1 RNA levels were
measured at baseline and at month 3 and month 6 after treatment. All
patients were treated with a combination of two reverse transcriptase inhibitors and a protease inhibitor (saquinavir EOF
[n = 28], ritonavir [n = 16], or
indinavir [n = 14]). Before treatment, 30 different
positions whose codons differed from the subtype B consensus sequence
were observed. Major mutations associated with protease inhibitor
resistance were not observed. No statistical correlation between the
number of amino acid differences and the treatment efficacy at month 3 ( Protease inhibitor regimens are
associated with a decrease in plasma human immunodeficiency virus type
1 (HIV-1) RNA levels, an increase in CD4 lymphocytes, and prolonged
survival of patients infected with HIV-1 (5). The appearance
of drug-resistant virus under this treatment is possible. Protease
inhibitor-resistant variants of HIV-1 have been described in vitro and
in vivo, and numerous mutations in the protease have been determined
(12, 13). Two categories of mutations have been reported:
major mutations, usually located in the active site of the protease,
and accessory mutations, located outside the active site. Both
categories are usually required for high-level resistance (1, 2,
11, 25). However, the presence of numerous accessory mutations
has been reported for patients who had not been previously exposed to a
protease inhibitor (1, 8, 12, 13, 16, 21). In vitro, these
accessory amino acid substitutions do not significantly alter the
susceptibility of the protease inhibitors (1, 12, 16).
However, during therapy, these amino acid substitutions have been
described to have an influence on 50 and 90% inhibitory concentration
increases (3, 14).
At baseline, the impact of these amino acid substitutions on response
to treatment including a protease inhibitor is not known. At baseline,
the influence of substitutions in the protease gene of patients naive
for protease inhibitors on the virologic response to combinations
including a protease inhibitor and two nucleoside reverse transcriptase
inhibitors was analyzed.
(This work was presented in part at the 2nd International Workshop on
HIV Drug Resistance and Treatment Strategies, Lake Maggiore, Italy, 24 to 27 June 1998, and at the 38th Interscience Conference on
Antimicrobial Agents and Chemotherapy, San Diego, Calif., 24 to 27 September 1998.)
At baseline, the sequence of the protease gene from 58 patients
who were protease inhibitor naive was characterized. Among these
patients, 12 had been treated previously with a combination of two
nucleoside reverse transcriptase inhibitors. Plasma HIV-1 RNA levels
were measured by Roche-Monitor assay (Roche Diagnostic Systems, Inc.,
Branchburg, N.J.), including the ultrasensitive assay, before
introduction of the protease inhibitor and at 3 and 6 months afterward
(lower limit of quantification, 20 copies/ml).
All patients were treated with two reverse transcriptase inhibitors and
a protease inhibitor with usual daily dosages: 28 patients received
saquinavir EOF (1,200 mg three times a day), 16 received ritonavir (600 mg twice a day), and 14 received indinavir (800 mg three times a day).
HIV-1 RNA was extracted from 200 µl of plasma by using the HCV
specimen preparation kit (Roche Diagnostic Systems, Inc.), reverse
transcribed to cDNA, and then directly amplified by nested PCR. The
primers used for cDNA synthesis and PCR amplification and cycle
conditions have been previously described (4). The entire
protease coding domain from the 58 patients before introduction of the
protease inhibitor was sequenced on an automated DNA sequencer (Applied
Biosystems model 377) and compared to the HIV-1 clade B consensus
sequence (15).
Statistical analyses were performed with nonparametric tests
(Spearman's rank correlation and Mann-Whitney U test).
Only one patient had a protease gene identical to the HIV-1 clade
B consensus sequence. The protease sequences of the other 57 patients
(98%) carried 1 to 9 amino acid differences from the consensus
sequence. The median number of substitutions was 4: 34 patients
harbored between 1 and 4 amino acid changes, and 23 had between 5 and 8 changes. A total of 30 positions differed from the consensus sequence,
while the most frequent changes (prevalence, >20%) were located at
positions 15, 35, 37, 41, 63, 77, and 93 (Table
1). The substitution at position 63 was
particularly frequent, as it was observed in 58% of the cases. The 63P
substitution (44%) represented the most common amino acid change in
the protease.
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Polymorphism of the Human Immunodeficiency Virus
Type 1 (HIV-1) Protease Gene and Response of HIV-1-Infected Patients to
a Protease Inhibitor
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
2.4 log) or month 6 (2.7 log) was observed. At baseline, genotypic
analysis of the HIV-1 protease gene of patients who have never received
a protease inhibitor does not allow prediction of the efficacy of
regimens containing a protease inhibitor.
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
RESULTS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
TABLE 1.
Incidence of amino acid substitutions in the
protease (n = 58)
The major amino acid mutations associated with reduced sensitivity to protease inhibitors, at positions 30, 48, 50, 82, 84, and 90, were not observed.
The median plasma HIV-1 RNA levels were 47.479 copies/ml before
introduction of the protease inhibitor, 162 copies/ml (2.4 log10) at month 3, and 89 copies/ml (2.7
log10) at month 6 after treatment. At months 3 and 6, 7 (12%) and 26 (45%) of 58 patients, respectively, achieved complete
suppression of HIV-1 RNA in plasma (<20 copies/ml).
With Spearman's rank correlation test, no statistical correlations between the number of protease amino acid substitutions and the decrease in HIV-1 RNA levels at months 3 and 6 were observed. Moreover, the presence of the 63P mutation did not influence the evolution of HIV-1 RNA levels.
The same results were observed when the tests were performed for each drug separately (saquinavir, ritonavir, and indinavir). Moreover, the numbers of amino acid substitutions were not significantly different between patients with complete therapeutic success (<20 copies/ml) and those without complete therapeutic success (>20 copies/ml) (Mann-Whitney U test).
| |
DISCUSSION |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
No association between the number of amino acid substitutions present at baseline and the response to treatment including a protease inhibitor was observed.
Many mutations in the protease gene that cause inhibitor resistance have been described in vitro and in vivo (1-14, 16-26). The most common major mutations associated in vivo with resistance to indinavir and ritonavir are at position 82, those associated with resistance to nelfinavir are at position 30, those associated with resistance to saquinavir are at positions 48 and 90, and those associated with resistance to amprenavir are at position 50 (2, 4, 17, 20, 23). These major mutations usually occur first in the presence of a protease inhibitor. With the exception of the mutation at position 90, they are located in the active site of the protease. These mutations are associated with phenotypic resistance by reducing the binding affinity of the protease inhibitor to HIV protease (6). In this study, these kinds of mutations in the patient's baseline protease sequence were not observed. However, many substitutions that have been described as accessory mutations, at positions 10, 33, 35, 36, 63, 71, and 77, were found in the protease from untreated subjects (12, 18, 20).
These accessory mutations are mainly located outside of the active site. Usually, molecular clones containing these changes do not reduce significantly the susceptibility to protease inhibitors in vitro. In vivo, rare cases of significant phenotypic change associated with these substitutions have been described (3). However, the combination of several accessory mutations with a major mutation is usually responsible for an increase in phenotypic resistance (1, 2, 11, 12, 25, 26).
Some observations of sequential early patient samplings have demonstrated that polymorphic changes precede the occurrence of resistance mutations, suggesting that polymorphic changes may serve as early markers of development of antiretroviral resistance (14). In this study, no statistical correlation between the number of substitutions in the protease gene from untreated patients at baseline and the response to treatment including a protease inhibitor was observed. Moreover, the number of accessory substitutions did not influence the rate of complete HIV-1 RNA viral load suppression (HIV-1 RNA level, <20 copies/ml).
At baseline, genotypic analysis of the HIV-1 protease gene from patients who have never received a protease inhibitor does not allow prediction of the efficacy of regimens containing a protease inhibitor.
| |
FOOTNOTES |
|---|
*
Corresponding author. Mailing address: Department of
Virology
CERVI, Hôpital Pitié-Salpêtrière,
47-83 Bd de l'Hôpital, 75651 Paris Cedex 13, France. Phone: 33 1 42 17 74 09. Fax: 33 1 42 17 74 11. E-mail:
vincent.calvez{at}psl.ap-hop-paris.fr.
| |
REFERENCES |
|---|
|
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
|
|---|
| 1. | Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, and M. Shivaprakash. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 374:569-571[Medline]. |
| 2. | Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276[Abstract]. |
| 3. | Craig, C., E. Race, J. Sheldon, L. Whittaker, S. Gilbert, A. Moffatt, S. Rose, S. Dissanayeke, G.-W. Chirn, I. B. Duncan, and N. Cammak. 1998. HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS 12:1611-1618[Medline]. |
| 4. | Eberle, J., B. Bechowsky, D. Rose, U. Hauser, K. von der Helm, L. Gurtler, and H. Nitschko. 1995. Resistance of HIV type 1 to proteinase inhibitor RO 31-8959. AIDS Res. Hum. Retroviruses 11:671-676[Medline]. |
| 5. |
Flexner, C.
1998.
HIV-protease inhibitors.
N. Engl. J. Med.
338:1281-1292 |
| 6. | Gulnik, S. V., L. I. Suvorov, B. Liu, B. Yu, B. Anderson, H. Mitsuya, and J. W. Erickson. 1995. Kinetic characterization and cross-resistance patterns of HIV-1 protease mutants selected under drug pressure. Biochemistry 34:9282-9287[Medline]. |
| 7. |
Ho, D. D.,
T. Toyoshima,
H. Mo,
D. J. Kempf,
D. Norbeck,
C. M. Chen,
N. E. Wideburg,
S. K. Burt,
J. W. Erickson, and M. K. Singh.
1994.
Characterization of human immunodeficiency virus type 1 variants with increased resistance to C2-symmetric protease inhibitor.
J. Virol.
68:2016-2020 |
| 8. | Jacobsen, H., M. Hanggi, M. Ott, I. B. Duncan, S. Owen, M. Andreoni, S. Vella, and J. Mous. 1996. In vivo resistance to a human immunodeficiency virus type 1 proteinase inhibitor: mutations, kinetics and frequencies. J. Infect. Dis. 173:1379-1387[Medline]. |
| 9. | Jacobsen, H., K. Yasargil, D. L. Winslow, J. C. Craig, A. Krohn, I. B. Duncan, and J. Mous. 1995. Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 206:527-534[Medline]. |
| 10. |
Kaplan, A. H.,
S. F. Michael,
R. S. Wehbie,
M. F. Knigge,
D. A. Paul,
L. Everitt,
D. J. Kempf,
D. W. Norbeck,
J. W. Erickson, and R. Swanstrom.
1994.
Selection of multiple HIV-1 variants with decreased sensitivity to an inhibitor of the viral protease.
Proc. Natl. Acad. Sci. USA
91:5597-5601 |
| 11. | King, R., S. Garber, and A. Winslow. 1995. Multiple mutations in the human immunodeficiency virus protease gene are responsible for decreased susceptibility to protease inhibitors. Antivir. Chem. Chemother. 6:80-88. |
| 12. | Kozal, M. J., N. Shah, N. Shen, R. Yang, R. Fucini, T. C. Merigan, D. D. Richman, D. Morris, E. Hubbell, M. Chee, and T. R. Gingeras. 1996. Extensive polymorphisms observed in HIV-1 clade B protease gene high-density oligonucleotide arrays. Nat. Med. 7:753-759. |
| 13. | Lech, W. J., G. Wang, Y. L. Yang, Y. Chee, K. Dorman, D. McCrae, L. C. Lazzeroni, J. W. Erickson, J. S. Sinsheimer, and A. H. Kaplan. 1996. In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J. Virol. 70:2038-2043[Abstract]. |
| 14. | Lloyd, R. M., Jr., J.-M. Lacroix, L. M. Hough, J. T. Houng, and P. M. Feorino. 1998. Polymorphic changes in HIV-1 pol as predictive molecular markers for resistance-associated mutations, abstr. I-76, p. 386. In Abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C. |
| 15. | Los Alamos National Laboratory. 1987. Clade B consensus. In G. Myers, S. F. Joseph, A. B. Rabson, and T. F. Smith (ed.), Human retroviruses and AIDS. Los Alamos National Laboratory, Los Alamos, N.Mex. |
| 16. | Markowitz, M., H. Mo, D. J. Kempf, D. W. Norbeck, T. N. Bhat, J. W. Erickson, and D. D. Ho. 1995. Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J. Virol. 69:701-706[Abstract]. |
| 17. | Molla, A., M. Korneyeva, Q. Gao, S. Vasavanonda, P. J. Schipper, H. M. Mo, M. Markowitz, T. Chernyavskiy, P. Niu, N. Lyons, A. Hsu, G. R. Granneman, D. D. Ho, C. A. Boucher, J. M. Leonard, D. W. Norbeck, and D. J. Kempf. 1996. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat. Med. 2:760-766[Medline]. |
| 18. | Molla, A., G. Granneman, E. Sun, and D. Kempf. 1998. Recent developments in HIV protease inhibitor therapy. Antivir. Res. 39:1-23[Medline]. |
| 19. |
Otto, M. J.,
S. Garber,
D. L. Winslow,
C. D. Reid,
P. Aldrich,
P. K. Jadhav,
C. E. Patterson,
C. N. Hodge, and Y. S. Cheng.
1993.
In vitro isolation and identification of human immunodeficiency virus (HIV) isolates with reduced sensitivity to C-2 symmetrical inhibitors of HIV type 1 protease.
Proc. Natl. Acad. Sci. USA
90:7543-7547 |
| 20. | Patick, A. K., H. Mo, M. Markowitz, K. Appelt, B. Wu, L. Musick, V. Kalish, S. Kaldor, S. Reich, D. Ho, and S. Webber. 1996. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob. Agents Chemother. 40:292-297[Abstract]. |
| 21. | Roberts, N., J. Craig, and J. Sheldon. 1998. Resistance and cross-resistance with saquinavir and other HIV protease inhibitors: theory and practice. AIDS 12:453-460[Medline]. |
| 22. | Roberts, N. 1995. Drug-resistance patterns of saquinavir and other HIV proteinase inhibitors. AIDS 9(Suppl. 2):S27-S32. |
| 23. | Schinazi, R., B. Larder, and J. Mellors. 1997. Mutations in retroviral genes associated with drug resistance. Int. Antivir. News 5:1-14. |
| 24. | Schmit, J. C., L. Ruiz, B. Clotet, A. Raventos, J. Tor, J. Leonard, J. Desmyter, E. De Clercq, and A. M. Vandamme. 1996. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 10:995-999[Medline]. |
| 25. | Tisdale, M., R. Myers, B. Maschera, N. Parry, N. Oliver, and E. Blair. 1995. Cross-resistance analysis of human immunodeficiency virus type 1 variants individually selected for resistance to five different protease inhibitors. Antimicrob. Agents Chemother. 39:1704-1710[Abstract]. |
| 26. | Vasudevachari, M. B., Y.-M. Zhang, H. Imamichi, T. Imamichi, J. Falloon, and N. P. Salzman. 1996. Emergence of protease inhibitor resistance mutations in human immunodeficiency virus type 1 isolates from patients and rapid screening procedure for their detection. Antimicrob. Agents Chemother. 40:2535-2541[Abstract]. |
Journal of Clinical Microbiology, September 1999, p. 2910-2912, Vol. 37, No. 9
0095-1137/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Vega, Y., Perez-Alvarez, L., Delgado, E., Munoz, M., Casado, G., Carmona, R., Sierra, M., Vazquez de Parga, E., Pinilla, M., Garcia, V., Medrano, L., Contreras, G., Thomson, M., Najera, R.
(2005). Oligonucleotide Ligation Assay for Detection of Mutations Associated with Reverse Transcriptase and Protease Inhibitor Resistance in Non-B Subtypes and Recombinant Forms of Human Immunodeficiency Virus Type 1. J. Clin. Microbiol.
43: 5301-5304
[Abstract] [Full Text] -
Damond, F., Brun-Vezinet, F., Matheron, S., Peytavin, G., Campa, P., Pueyo, S., Mammano, F., Lastere, S., Farfara, I., Simon, F., Chene, G., Descamps, D.
(2005). Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors. J. Clin. Microbiol.
43: 484-487
[Abstract] [Full Text] -
Colson, P., Henry, M., Tourres, C., Lozachmeur, D., Gallais, H., Gastaut, J. A., Moreau, J., Tamalet, C.
(2004). Polymorphism and Drug-Selected Mutations in the Protease Gene of Human Immunodeficiency Virus Type 2 from Patients Living in Southern France. J. Clin. Microbiol.
42: 570-577
[Abstract] [Full Text] -
Masquelier, B., Droz, C., Dary, M., Perronne, C., Ferre, V., Spire, B., Descamps, D., Raffi, F., Brun-Vezinet, F., Chene, G., the APROCO/COPILOTE Study Group,
(2003). R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen. Antimicrob. Agents Chemother.
47: 3623-3626
[Abstract] [Full Text] -
Shafer, R. W.
(2002). Genotypic Testing for Human Immunodeficiency Virus Type 1 Drug Resistance. Clin. Microbiol. Rev.
15: 247-277
[Abstract] [Full Text] -
Beck, I. A., Mahalanabis, M., Pepper, G., Wright, A., Hamilton, S., Langston, E., Frenkel, L. M.
(2002). Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors. J. Clin. Microbiol.
40: 1413-1419
[Abstract] [Full Text] -
Servais, J., Lambert, C., Fontaine, E., Plesséria, J.-M., Robert, I., Arendt, V., Staub, T., Schneider, F., Hemmer, R., Burtonboy, G., Schmit, J.-C.
(2001). Variant Human Immunodeficiency Virus Type 1 Proteases and Response to Combination Therapy Including a Protease Inhibitor. Antimicrob. Agents Chemother.
45: 893-900
[Abstract] [Full Text] -
Vergne, L., Peeters, M., Mpoudi-Ngole, E., Bourgeois, A., Liegeois, F., Toure-Kane, C., Mboup, S., Mulanga-Kabeya, C., Saman, E., Jourdan, J., Reynes, J., Delaporte, E.
(2000). Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients. J. Clin. Microbiol.
38: 3919-3925
[Abstract] [Full Text]
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»